Male fertility diagnostics continues to face challenges related to sample quality, standardization, and clinically relevant insight into male fertilization potential. RSI has developed proprietary devices, including the ProteX™ collection system and the NovoSort® sperm processing technology, designed to maintain sperm quality and facilitate standardized laboratory workflows. Building on RSI's expertise, the MoU aims to evaluate how JUNO-Checked can be deployed on high-quality samples using RSI's devices, providing clinicians with clinically actionable, function-based insights to better assess male fertility and support optimal patient treatment.

The MoU establishes a framework for jointly evaluating a potential model in which JUNO-Checked is performed on samples collected and processed using RSI's products. During the term of the MoU, the parties intend to examine technical compatibility, operational feasibility, and relevant regulatory and commercial considerations to address this important clinical need in US fertility care.

The MoU is non-binding and does not include agreed commercial terms, exclusivity arrangements, or commitments to enter into definitive agreements. Building on active dialogues with potential partners, including the MoU announced on 16 January 2026, Spermosens actively engages with partners across multiple segments and markets to support the introduction of JUNO-Checked to fertility clinics and patients worldwide. Spermosens values its partners' expertise and market position and is committed to building long-term relationships established on a foundation of trust.

Tore Duvold, CEO of Spermosens, comments: "JUNO-Checked addresses a critical and under-served dimension of male fertility diagnostics, offering clinically actionable insights that can support better patient treatment. RSI's medical devices enable high-quality sample handling, which is essential for realizing the full potential of our diagnostic. We have great respect for RSI and the expertise they bring, and this MoU provides an exciting opportunity to evaluate a model that could bring JUNO-Checked to fertility clinics in the United States."

Sam Marple, CEO of RSI comments: "JUNO-Checked introduces a novel, function-based perspective to male fertility assessment, which aligns well with the clinical challenges our devices are designed to address. We are pleased to engage in this dialogue and look forward to exploring how combining our solutions could provide clinicians with richer, more actionable diagnostic information."

About Spermosens AB
Spermosens AB is a biotechnology company focused on developing diagnostic solutions to improve fertility treatments. Based in Sweden, Spermosens specializes in the development of JUNO-Checked, a diagnostic method intended to provide clinically relevant insight into male fertility potential. The company's strategy is to demonstrate clinical value and pursue commercialization through partnerships and licensing agreements. Spermosens' shares are listed on the Spotlight Stock Market. The shares have ISIN code SE0015346424 and are traded under the short name SPERM. For more information, see www.spermosens.com

About Reproductive Solutions Inc.
RSI Technology Group, LLC (RSI) is a US-based medical device company focused on developing solutions for sperm collection and preparation used in diagnostic and assisted reproduction workflows. RSI's proprietary technologies include the ProteX™ collection device and the NovoSort® sperm processing technology, designed to support sample integrity and standardized laboratory handling. For more information, see www.rsifertility.com

For further information, please contact:
Tore Duvold, CEO
E-mail: info@spermosens.com